Pulmatrix
Open
$1.28
Prev. Close
$1.28
High
$1.28
Low
$1.28
Market Snapshot
$4.53M
-0.9
-2.62
$7.81M
2
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2014-03-21. The firm is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
emptyResult
Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2014-03-21. The firm is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
Recently from Cashu
Pulmatrix Merges with Eos SENOLYTIX to Revolutionize Anti-Aging Treatments
Pulmatrix and Eos SENOLYTIX Forge a New Path in Anti-Aging Treatments On March 26, 2026, Pulmatrix, Inc. announces a definitive merger with Eos SENOLYTIX, marking a significant development in the biot…
Pulmatrix Pursues New Merger Opportunities After Cullgen Agreement Termination
Pulmatrix Explores New Merger Avenues Following Cullgen Termination Pulmatrix, Inc. finds itself at a crossroads as it grapples with the recent termination of its merger agreement with Cullgen Inc. Th…
Pulmatrix Navigates Merger Setback with Optimism for Future Biopharmaceutical Opportunities
Pulmatrix Faces Merger Setback but Remains Optimistic About Future Opportunities Pulmatrix, Inc., a biopharmaceutical company known for developing innovative inhaled therapeutics, experiences a signif…
Pulmatrix Shifts Focus Amid Merger Termination, Seeks New Strategic Partnerships
Pulmatrix Faces Merger Setback, Shifts Focus to New Opportunities In a significant development for Pulmatrix, Inc., the company learns of the termination of its Merger Agreement with Cullgen Inc. as o…